Euretina Congress – Paris 2019
The 19th EURETINA meeting, held in Paris between 5 and 8 September 2019, was the largest in the history of the Society and is today holding the title of largest retina meeting in the world.
The benefits of a T&E injection regimen for patients with neovascular AMD
Prof. Gemmy Cheung, MD, FRCOphth, Associate Professor and Senior Consultant at the Singapore National Eye Center, speaks about the benefits and increasing popularity of the T&E injection regimen for patients with neovascular AMD.
Real-world evidence confirms the good outcomes of aflibercept in DME
Jean-François Korobelnik, MD, Professor of Ophthalmology at the University Hospital of Bordeaux (France) speaks about real-world evidence on the treatment of DME with aflibercept. Recent data confirm the results of randomized clinical trials.
The importance of imaging choroidal hemodynamics
Marco Lupidi, MD, PhD, of the Biomedical and Surgical Sciences Department of the University of Perugia, Italy, speaks about his studies on choroidal hemodynamics in central serous chorioretinopathy (CSCR).
Observing blood flow variations through multimodal imaging, and particularly OCTA, allows clinicians to better understand the course of the disease and the effects of treatment.
ATLANTIC study shows good results of aflibercept in PCV
Rufino Silva, MD, PhD, Professor of Ophthalmology at the University of Coimbra, Portugal, speaks about the results of the the ATLANTIC study, a multicentered randomized clinical trial performed on a Caucasian population with polypoidal choroidal vasculopathy (PCV). Patients were treated with T&E aflibercept, with or without additional photodynamic therapy (PDT).
Diabetic Macular Edema, treatment options and criteria
Sobha Sivaprasad, MD, Professor and Consultant Ophthalmologist at Moorfields Eye Hospital, London, speaks about the current options and criteria for the treatment of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Anti-VEGF injections are first-line therapy for center-involving DME and are gaining popularity for PDR.
Optogenetics for vision restoration
Prof. José-Alain Sahel, MD, of the University of Pittsburgh School of Medicine, USA, speaks about optogenetics for vision restoration in rare genetic retinal diseases, and the preliminary results of a study applying optogenetics to the treatment of retinitis pigmentosa.
OCTA improves diagnosis of retinal diseases and several systemic conditions
Nicole Eter, MD, of the University Hospital of Münster, Germany, speaks about OCTA as an invaluable addition to multimodal imaging, able for the first time to quantify microcirculation.
Dealing with ILM peeling in unusual situations
Saumil Sheth, MD, MS, FRCS, of the Envision Eye Hospital, Mumbai, India, speaks about two unusual and complicated cases of internal limiting membrane (ILM) peeling and gives pearls on how to deal with these challenging situations.
T&E injection regimen and the impact of fluid on visual outcomes
Varun Chaudhary MD, FRCSC, Chief of Ophthalmology and Associate Professor at McMaster University, Canada, speaks about T&E injection regimen in the management of AMD and the role of fluid in determining treatment outcomes.
When to use anti-VEGF injections to treat diabetic retinopathy
Marco A. Zarbin, MD, PhD, of Rutger New Jersey Medical School, USA, speaks about the use anti-VEGF agents to treat diabetic retinopathy, explaining when we should intervene based on the evidence from trials.
Large meta analysis of anti-VEGF outcomes provides evidence on best regimen, injection frequency
Valentina Sarao, MD of the Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy, speaks about a large meta-analysis of the results obtained with all three anti-VEGF agents in neovascular AMD. Data on more than 100,000 eyes from randomized and observational studies were included. Best injection regimen and injection frequency were investigated.